期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米治疗多发性骨髓瘤致严重带状疱疹一例 被引量：1

原文传递
导出
摘要 患者男，73岁，汉族，因咳嗽、活动后气短4个月就诊于外院，行血常规提示全血细胞减少，胸部CT提示右肺尖后26mm×36mm软组织影，邻近肋骨可见囊状骨破坏。骨髓穿刺提示异常浆细胞0．52，诊断多发性骨髓瘤（MM）。
作者 澹台林芳 张健
机构地区 兰州军区兰州总医院保健一部
出处 《白血病．淋巴瘤》 CAS 2012年第8期509-510,共2页 Journal of Leukemia & Lymphoma
关键词 多发性骨髓瘤 硼替佐米 疱疹 带状
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1赵娜（综述）,杨俊杰（审校）.蛋白酶体抑制剂硼替佐米治疗多发性骨髓瘤的分子机制[J].白血病．淋巴瘤,2011,20(11):698-700. 被引量：5
  • 2陈飞,王玉娟,张克俭,左学兰,詹竹英.硼替佐米联合地塞米松及沙利度胺治疗多发性骨髓瘤临床观察[J].临床血液学杂志,2011,24(2):176-177. 被引量：17
  • 3钟玉萍,陈世伦.硼替佐米治疗复发难治性多发性骨髓瘤43例[J].白血病．淋巴瘤,2009,18(9):538-540. 被引量：6
  • 4Jones JO, Arvin AM. Inhibition of the NF- K B pathway by varicella zoster virus in vitro and in human epidermal ceils in vivo. J Virol, 2006, 80:5113-5124.
  • 5Berges C, Haberstock H, Fuchs D, et al. Proteasome inhibition suppresses essential immune functions of human CD ~ T cells. Immunology, 2008, 124: 234-246.
  • 6Heider U,V'Rademacher J, Kaiser M, et al. Decrease in CD: T-cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma Leuk, 2010, 10: 134-137.
  • 7Seok J, Kim KK, Young RD, et al. Low-dose acyciovir is effective for prevention of herpes zoster in myeloma patients treated withbortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Leukemia, 2010, 24: 1350-1356.
  • 8Aoki T, Nishiyama T, Imahashi N, et al. Efficacy of continuous,daily, oral,ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study. Jpn J Clin Oncol, 2011, 41: 876-881.

二级参考文献50

  • 1邱录贵.多发性骨髓瘤的发病与国人特点[J].中国实用内科杂志：临床前沿版,2006,26(6):886-888. 被引量：52
  • 2Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood, 2004, 103: 20-32.
  • 3Bataille R. Harousseau JL. Multiple myeloma. The New England Journal of Medicine, 1997, 336: 1657-1664.
  • 4The UK Myeloma Forum Guidelines Working Group.Diagnosis and management of multiple myeloma. Bri J Haematol, 2001, 115: 522-540.
  • 5Blad e, J, Samson D, Reeee D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transplant. Br J Haematol. 1998. 102:1115-1123.
  • 6Popat R, Oakervee H, Williams C, et al. Bortezomid,low-dose intravenous melphalan,and dexamethasone for patients with relapsed muhiple myeloma. Br J Haematol, 2009, 144: 887-894.
  • 7Podar K, Tai YT, Hideshima T, et al. Emerging therapies for multiple myeloma. Expert Opin Emerg Dnlgs, 2009, 14: 99-127.
  • 8Berenson JR, Yang HH, Vescio RA, et al. Safety and efficacy of bortezomid and melphalan combination in patients with relapsed or refractory multiple myeloma:updated results of a phase 1/2 study after longer follow-up. Ann Hematol, 2008, 87:623-631.
  • 9BladeJ, Sonneveld P, San Miguel JF, et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory. muhiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma, 2008, 8: 352-355.
  • 10RICHARDSON P G,BARLOGIE B,BERENSON J,et al.A phase 2 study of bortezomib in relapsed/refractory myeloma[J].N Engl J Med,2003,348:2609-2617.

共引文献25

同被引文献7

引证文献1

二级引证文献2

白血病．淋巴瘤
2012年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部